PT97034B - Processo para a producao de moleculas de ligacao ao antigenio cd25 - Google Patents

Processo para a producao de moleculas de ligacao ao antigenio cd25 Download PDF

Info

Publication number
PT97034B
PT97034B PT97034A PT9703491A PT97034B PT 97034 B PT97034 B PT 97034B PT 97034 A PT97034 A PT 97034A PT 9703491 A PT9703491 A PT 9703491A PT 97034 B PT97034 B PT 97034B
Authority
PT
Portugal
Prior art keywords
amino acid
ser
gly
thr
ile
Prior art date
Application number
PT97034A
Other languages
English (en)
Portuguese (pt)
Other versions
PT97034A (pt
Inventor
Peter Lloyd Amlot
Arne Nalpon Akbar
Gunther Heinrich
Salvatore Cammisuli
Original Assignee
Royal Free Hosp School Med
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT97034(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Royal Free Hosp School Med, Novartis Ag filed Critical Royal Free Hosp School Med
Publication of PT97034A publication Critical patent/PT97034A/pt
Publication of PT97034B publication Critical patent/PT97034B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
PT97034A 1990-03-16 1991-03-14 Processo para a producao de moleculas de ligacao ao antigenio cd25 PT97034B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (2)

Publication Number Publication Date
PT97034A PT97034A (pt) 1991-10-31
PT97034B true PT97034B (pt) 1998-07-31

Family

ID=26296798

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97034A PT97034B (pt) 1990-03-16 1991-03-14 Processo para a producao de moleculas de ligacao ao antigenio cd25

Country Status (23)

Country Link
US (2) US6521230B1 (enExample)
EP (1) EP0449769B1 (enExample)
JP (1) JP2585475B2 (enExample)
AT (1) ATE98655T1 (enExample)
AU (1) AU635401B2 (enExample)
CA (1) CA2038279C (enExample)
CY (1) CY1977A (enExample)
DE (2) DE19975033I2 (enExample)
DK (1) DK0449769T3 (enExample)
ES (1) ES2061216T3 (enExample)
FI (3) FI103131B (enExample)
HK (1) HK53797A (enExample)
HU (2) HUT60768A (enExample)
IE (1) IE65062B1 (enExample)
IL (1) IL97545A (enExample)
LU (1) LU90383I2 (enExample)
MY (1) MY106161A (enExample)
NL (1) NL990008I2 (enExample)
NZ (1) NZ237434A (enExample)
PL (1) PL170321B1 (enExample)
PT (1) PT97034B (enExample)
SA (1) SA92120358B1 (enExample)
TW (1) TW213486B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
DE69835216T2 (de) 1997-07-25 2007-05-31 Nichia Corp., Anan Halbleitervorrichtung aus einer nitridverbindung
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE372349T1 (de) * 1998-07-27 2007-09-15 Novartis Pharma Gmbh Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
AU2002315271B2 (en) * 2001-04-06 2006-08-03 University Of Bristol Use of CD25 binding molecules in steroid-resistant patients
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
CA2718184A1 (en) 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
JP5795167B2 (ja) 2008-03-13 2015-10-14 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
CA2717812A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2016083468A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CN110582303A (zh) 2017-04-20 2019-12-17 Adc治疗有限公司 使用抗cd25抗体-药物缀合物的组合疗法
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
WO2020248938A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗cd25抗体及其应用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022221669A1 (en) 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
US20250361308A1 (en) 2022-07-01 2025-11-27 Neurogene Inc. NEO-2/15 Variants and Uses Thereof for Preferentially Stimulating T-Regulatory Cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
ES2059539T3 (es) * 1987-12-02 1994-11-16 Becton Dickinson Co Metodo para la prevencion de la enfermedad del injerto frente al huesped.
KR900700134A (ko) * 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
ES2061216T3 (es) 1994-12-01
IL97545A0 (en) 1992-06-21
PL289436A1 (en) 1992-02-24
DK0449769T3 (da) 1994-02-21
HU910761D0 (en) 1991-09-30
DE19975033I2 (de) 2007-01-04
CY1977A (en) 1997-09-05
FI981799L (fi) 1998-08-21
HK53797A (en) 1997-05-02
FI103131B1 (fi) 1999-04-30
SA92120358B1 (ar) 2004-01-25
ATE98655T1 (de) 1994-01-15
FI103131B (fi) 1999-04-30
FI19991788L (fi) 1999-08-23
TW213486B (enExample) 1993-09-21
HUT60768A (en) 1992-10-28
HU211885A9 (en) 1995-12-28
US6383487B1 (en) 2002-05-07
MY106161A (en) 1995-03-31
CA2038279A1 (en) 1991-09-17
FI104047B (fi) 1999-11-15
IE65062B1 (en) 1995-10-04
DE69100768T2 (de) 1994-05-11
DE69100768D1 (de) 1994-01-27
FI911275A0 (fi) 1991-03-14
PL170321B1 (pl) 1996-11-29
LU90383I2 (fr) 1999-06-07
FI981799A0 (fi) 1998-08-21
NL990008I2 (nl) 1999-10-01
NZ237434A (en) 1992-08-26
PT97034A (pt) 1991-10-31
CA2038279C (en) 1999-03-09
AU635401B2 (en) 1993-03-18
US6521230B1 (en) 2003-02-18
FI911275L (fi) 1991-09-17
JP2585475B2 (ja) 1997-02-26
IL97545A (en) 2000-06-29
IE910867A1 (en) 1991-09-25
JPH04316600A (ja) 1992-11-06
EP0449769A1 (en) 1991-10-02
FI19991788A7 (fi) 1999-08-23
EP0449769B1 (en) 1993-12-15
NL990008I1 (nl) 1999-06-01
FI104047B1 (fi) 1999-11-15
AU7290991A (en) 1991-09-19

Similar Documents

Publication Publication Date Title
PT97034B (pt) Processo para a producao de moleculas de ligacao ao antigenio cd25
CN100549031C (zh) 突变的无激活作用的IgG2结构域和插入该结构域的抗CD3抗体
DE69230545T2 (de) Antikörperderivate
CA2114015C (en) Recombinant antibodies for human therapy
US20020150580A1 (en) Recombinant antibodies for human therapy
JPH04502408A (ja) ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
JPH08511421A (ja) 人化抗体
US9376485B2 (en) Neutralizing antibody for epstein barr virus-associated disease
WO2003026692A2 (en) Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
AU2002329423A1 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
US6919077B2 (en) LFA-1 alpha subunit antibodies and methods of use
KR20240004761A (ko) 항-baffr 항체를 사용한 전신 홍반성 루푸스의 치료

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910710

FG3A Patent granted, date of granting

Effective date: 19980415

PC3A Transfer or assignment

Free format text: 19990408 UNIVERSITY COLLEGE LONDON GB

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130415